Related Experiment Videos
Colorectal cancer and non-steroidal anti-inflammatory drugs
1Third Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan. ota@saitama-med.ac.jp
Abstract:
Non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or reduce the occurrence of colorectal cancers. Anti-carcinogenic properties of NSAIDs have been demonstrated in epidemiological studies of humans and experimental animals. In addition, clinical studies of familial adenomatous polyposis and sporadic adenomas have demonstrated that NSAIDs induce regression of colorectal adenomas and prevent formation of these tumors. NSAIDs thus induce early disruption of the adenoma-carcinoma sequence and may mainly suppress subsequent cancer formation at adenoma stage. The mechanism of the anti-carcinogenic effect of these drugs is not known, but results of most studies support that cyclooxygenase-2 (an inducible isoform of prostaglandin synthetase, COX-2) is a major target of NSAIDs in this effect. Recent immunohistochemical studies have revealed that COX-2 is expressed not in tumor cells but in interstitial cells of colonic adenomas. Accordingly, NSAIDs may exhibit anti-carcinogenic property through the inhibition of prostaglandin production by COX-2 expressing interstitial cells. Future research should be focused on the role of prostaglandins in the interaction of tumor cells and interstitial cells in colon carcinogenesis.
Insights
Non-steroidal anti-inflammatory drugs (NSAIDs) can prevent colorectal cancer by targeting cyclooxygenase-2 (COX-2). These drugs may inhibit prostaglandin production in interstitial cells, disrupting early tumor development.
Area of Science:
- Oncology
- Pharmacology
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) show promise in preventing and reducing colorectal cancers.
- Studies indicate NSAIDs can induce regression of colorectal adenomas and prevent tumor formation.
Purpose of the Study:
- To investigate the anti-carcinogenic mechanisms of NSAIDs in colorectal cancer.
- To identify the role of cyclooxygenase-2 (COX-2) in NSAID-mediated chemoprevention.
Main Methods:
- Review of epidemiological, animal, and clinical studies on NSAIDs and colorectal adenomas.
- Analysis of immunohistochemical data on COX-2 expression in colonic adenomas.
Main Results:
- NSAIDs disrupt the adenoma-carcinoma sequence, primarily at the adenoma stage.
- Cyclooxygenase-2 (COX-2) is identified as a key target of NSAIDs.
- COX-2 is expressed in interstitial cells of colonic adenomas, not tumor cells.
Conclusions:
- NSAIDs may exert anti-carcinogenic effects by inhibiting prostaglandin production via COX-2 in interstitial cells.
- Further research is needed on the role of prostaglandins in colon carcinogenesis and cell interactions.